Table 4 Staging systems of patients with localized PG-DLBCL
Staging system | Stage | N (%) | 5-year RFS | P value | 5-year OS | P value | |
|---|---|---|---|---|---|---|---|
Ann Arbor staging with Musshoff modification | I (Ie1–Ie2) | 62 (61) | 86.8 ± 5.1 % | 0.423 | 87.6 ± 5.3 % | 0.428 | |
II (IIe1–IIe2) | 39 (52) | 77.9 ± 7.4 % | 76.1 ± 7.7 % | ||||
IPI | Low | 65 (64) | 89.4 ± 4.5 % | 0.006 | 90.9 ± 4.4 % | 0.004 | |
L–I | 19 (19) | 93.8 ± 6.1 % | 93.8 ± 6.1 % | ||||
H–I | 4 (4) | 56.3 ± 14.8 % | 55.6 ± 14.9 % | ||||
High | 13 (13) | 50.0 ± 2.5 % | 50.0 ± 2.5 % | ||||
Lugano classification | Early stage (I–II) | 82 (81) | 86.5 ± 4.5 % | 0.039 | 85.4 ± 4.9 % | 0.044 | |
Late stage (IIE) | 19 (19) | 71.1 ± 11.0 % | 76.0 ± 10.5 % | ||||
Paris staging system | T | 1 | 0 | – | 0.022 | – | 0.029 |
2 | 40 (40) | 95.8 ± 4.1 % | 94.7 ± 5.1 % | ||||
3 | 43 (42) | 71.3 ± 8.1 % | 73.7 ± 8.0 % | ||||
4 | 18 (18) | 81.1 ± 9.9 % | 80.4 ± 10.2 % | ||||
N | 0 | 48 (48) | 93.5 ± 4.5 % | <0.001 | 92.2 ± 5.4 % | <0.001 | |
1 | 51 (50) | 75.0 ± 6.9 % | 77.2 ± 6.7 % | ||||
2 | 2 (2) | 50.0 ± 35.4 % | 50.0 ± 35.4 % | ||||
3 | 0 | – | – | ||||
M | 0 | 95 (94) | 85.9 ± 4.2 % | 0.018 | 86.2 ± 4.3 % | 0.020 | |
1 | 6 (6) | 50.0 ± 20.4 % | 50.0 ± 20.4 % | ||||
2 | 0 | – | – | ||||